CGTX
Cognition Therapeutics Inc

3,910
Mkt Cap
$149.18M
Volume
113.00
52W High
$3.83
52W Low
$0.2223
PE Ratio
-3.41
CGTX Fundamentals
Price
$1.62
Prev Close
$1.69
Open
$1.70
50D MA
$1.66
Beta
1.37
Avg. Volume
1.01M
EPS (Annual)
-$0.855
P/B
3.91
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Cognition Therapeutics in a research report on Thursday...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Q1 Earnings Forecast for CGTX Issued By B. Riley
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities research analysts at B. Riley issued their Q1 2026 earnings per share estimates for Cognition Therapeutics in a report issued on...
MarketBeat·18d ago
News Placeholder
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the stock, MarketBeat.com reports...
MarketBeat·19d ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Announces Quarterly Earnings Results
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus...
MarketBeat·1mo ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Cognition Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago

Latest CGTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.